Plasmodium falciparum resistance to artemisinin-based combination therapies: A sword of Damocles in the path toward malaria elimination
Open accessThe DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
The use of artemisinin-based combination therapies (ACTs), which combine an artemisinin derivative with a partner drug, in the treatment of uncomplicated malaria has largely been responsible for the significant reduction in malaria-related mortality in tropical and subtropical regions. ACTs have also played a significant role in the 18% decline in the incidence of malaria cases from 2010 to 2016. However, this progress is seriously threatened by the reduced clinical efficacy of artemisinins, which is characterised by delayed parasitic clearance and a high rate of recrudescence, as reported in 2008 in Western Cambodia. Resistance to artemisinins has already spread to several countries in Southeast Asia. Furthermore, resistance to partner drugs has been shown in some instances to be facilitated by pre-existing decreased susceptibility to the artemisinin component of the ACT. A major concern is not only the spread of these multidrug-resistant parasites to the rest of Asia but also their possible appearance in Sub-Saharan Africa, the continent most affected by malaria, as has been the case in the past with parasite resistance to other antimalarial treatments. It is therefore essential to understand the acquisition of resistance to artemisinins by Plasmodium falciparum to adapt malaria treatment policies and to propose new therapeutic solutions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weltgesundheitsorganisation (2005) · Cited by 3,799
Artemisinin Resistance in Plasmodium falciparum Malaria
Dondorp, A. M., Nosten, F., Yi, P., Das, D., Phyo, A. P., Tarning, J., Lwin, K. M., Ariey, F., Hanpithakpong, W., Lee, S. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808859 · Cited by 3,424 · cited 12×
“Although there is no current evidence that artemisinin resistance has emerged outside Asia, this finding reinforces the need for routine monitoring and surveillance of the therapeutic efficacy and safety of artemisinins and ACTs, as recommended by the WHO, for effective case management and early detection of resistanc…”
BackgroundMethodInfluentialQuantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique
Desjardins, R. E., Canfield, C. J., Haynes, J. D., & Chulay, J. D. (1979) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.16.6.710 · Cited by 2,514 · cited 10×
“Although there is no current evidence that artemisinin resistance has emerged outside Asia, this finding reinforces the need for routine monitoring and surveillance of the therapeutic efficacy and safety of artemisinins and ACTs, as recommended by the WHO, for effective case management and early detection of resistanc…”
MethodInfluentialA molecular marker of artemisinin-resistant Plasmodium falciparum malaria
Ariey, F., Witkowski, B., Amaratunga, C., Beghain, J., Langlois, A.-C., Khim, N., Kim, S., Duru, V., Bouchier, C., Ma, L., et al. (2014) · Nature · doi:10.1038/nature12876 · Cited by 2,090 · cited 3×
“The high survival rate of parasites in RSA correlates with both pfk13 polymorphisms and clinical outcomes [6,74,80].”
BackgroundSelf-citationEvidence of Artemisinin-Resistant Malaria in Western Cambodia
Noedl, H., Se, Y., Schaecher, K., Smith, B. L., Socheat, D., & Fukuda, M. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0805011 · Cited by 1,785 · cited 2×
“Artemisinin resistance was first correlated with delayed parasitic clearance after the first 3 days of treatment following artemisinin monotherapy or ACTs and higher rates of clinical failures due to increased parasitic recrudescence [22,53].”
BackgroundDondorp, A. M., Fanello, C. I., Hendriksen, I. C., Gomes, E., Seni, A., Chhaganlal, K. D., Bojang, K., Olaosebikan, R., Anunobi, N., Maitland, K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61924-1 · Cited by 1,022
Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study
Phyo, A. P., Nkhoma, S., Stepniewska, K., Ashley, E. A., Nair, S., McGready, R., ler Moo, C., Al-Saai, S., Dondorp, A. M., Lwin, K. M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60484-x · Cited by 924 · cited 1×
“Resistance to artemisinins is heritable and therefore has a clear genetic basis [5,62].”
BackgroundMefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number
Price, R. N., Uhlemann, A.-C., Brockman, A., McGready, R., Ashley, E., Phaipun, L., Patel, R., Laing, K., Looareesuwan, S., White, N. J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16767-6 · Cited by 853
K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates
Straimer, J., Gnädig, N. F., Witkowski, B., Amaratunga, C., Duru, V., Ramadani, A. P., Dacheux, M., Khim, N., Zhang, L., Lam, S., et al. (2015) · Science · doi:10.1126/science.1260867 · Cited by 728 · cited 1×
“survival rates of ring stage parasites is dependent on the genetic background of the parasites [73].”
BackgroundSelf-citationGenetic architecture of artemisinin-resistant Plasmodium falciparum
Miotto, O., Amato, R., Ashley, E. A., MacInnis, B., Almagro-Garcia, J., Amaratunga, C., Lim, P., Mead, D., Oyola, S. O., Dhorda, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3189 · Cited by 609
The kelch repeat superfamily of proteins: propellers of cell function
Adams, J., Kelso, R., & Cooley, L. (2000) · Trends in Cell Biology · doi:10.1016/s0962-8924(99)01673-6 · Cited by 600 · cited 1×
“The exact function of this protein is not yet known, but it shares homologies with the human Keap1 protein, involved in the cell response to oxidative stress [6,1].”
BackgroundA Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms
Ménard, D., Khim, N., Beghain, J., Adegnika, A. A., Shafiul-Alam, M., Amodu, O., Rahim-Awab, G., Barnadas, C., Berry, A., Boum, Y., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513137 · Cited by 551 · cited 3×
“However, to date, the KARMA (K13 Artemisinin Resistance Multicenter Assessment) study, analysing more than 14,000 parasite samples from 59 countries in which malaria is endemic, determined, on the basis of pfk13 monitoring, that artemisinin resistance is confined to Southeast Asia and has not yet spread and/or emerged…”
BackgroundArtesunate combinations for treatment of malaria: meta-analysis
(2004) · The Lancet · doi:10.1016/s0140-6736(03)15162-8 · Cited by 538
Kublin, J. G., Cortese, J. F., Njunju, E. M., G. Mukadam, R. A., Wirima, J. J., Kazembe, P. N., Djimdé, A. A., Kouriba, B., Taylor, T. E., & Plowe, C. V. (2003) · The Journal of Infectious Diseases · doi:10.1086/375419 · Cited by 508
Mechanisms of Resistance of Malaria Parasites to Antifolates
Gregson, A., & Plowe, C. V. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.1.4 · Cited by 499
Amaratunga, C., Lim, P., Suon, S., Sreng, S., Mao, S., Sopha, C., Sam, B., Dek, D., Try, V., Amato, R., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00487-9 · Cited by 493 · cited 3×
“amplification are sensitive to piperaquine [3,4,24,83].”
BackgroundImwong, M., Suwannasin, K., Kunasol, C., Sutawong, K., Mayxay, M., Rekol, H., Smithuis, F. M., Hlaing, T. M., Tun, K. M., van der Pluijm, R. W., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30048-8 · Cited by 484 · cited 1×
“Recent data suggest that piperaquine resistance has developed in a background of artemisinin resistance [3,29,60,68,71].”
BackgroundRare coding variants in the phospholipase D3 gene confer risk for Alzheimer’s disease
Cruchaga, C., Karch, C. M., Jin, S. C., Benitez, B. A., Cai, Y., Guerreiro, R., Harari, O., Norton, J., Budde, J., Bertelsen, S., et al. (2014) · Nature · doi:10.1038/nature12825 · Cited by 461
Return of Chloroquine Antimalarial Efficacy in Malawi
Laufer, M. K., Thesing, P. C., Eddington, N. D., Masonga, R., Dzinjalamala, F. K., Takala, S. L., Taylor, T. E., & Plowe, C. V. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062032 · Cited by 432
Takala-Harrison, S., Jacob, C. G., Arze, C., Cummings, M. P., Silva, J. C., Dondorp, A. M., Fukuda, M. M., Hien, T. T., Mayxay, M., Noedl, H., et al. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu491 · Cited by 422
Amato, R., Lim, P., Miotto, O., Amaratunga, C., Dek, D., Pearson, R. D., Almagro-Garcia, J., Neal, A. T., Sreng, S., Suon, S., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30409-1 · Cited by 401 · cited 3×
“DHA/PPQ resistance was confirmed by several reports and correlated with pfk13 polymorphism, plasmepsin 2-3 gene amplification and single copies of the pfmdr1 gene [4,83].”
BackgroundResultWitkowski, B., Duru, V., Khim, N., Ross, L. S., Saintpierre, B., Beghain, J., Chy, S., Kim, S., Ke, S., Kloeung, N., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30415-7 · Cited by 381
Discovery, mechanisms of action and combination therapy of artemisinin
Cui, L., & Su, X.-Z. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.68 · Cited by 371 · cited 1×
“Together, these events cause oxidative stress, leading to irreversible parasite damage and parasite death [17].”
BackgroundThe pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic physiology
Buffet, P. A., Safeukui, I., Deplaine, G., Brousse, V., Prendki, V., Thellier, M., Turner, G. D., & Mercereau-Puijalon, O. (2011) · Blood · doi:10.1182/blood-2010-04-202911 · Cited by 368 · cited 3×
“This phenomenon is important in the pathogenesis because mature parasites are able to adhere to endothelial cells, blood cells and platelets which prevent their circulation in the bloodstream and theywill therefore be able to escape retention by the spleen [12].”
BackgroundPrice, R. N., Uhlemann, A.-C., van Vugt, M., Brockman, A., Hutagalung, R., Nair, S., Nash, D., Singhasivanon, P., Anderson, T. J. C., Krishna, S., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/503423 · Cited by 317
Increased Tolerance to Artemisinin in Plasmodium falciparum Is Mediated by a Quiescence Mechanism
Witkowski, B., Lelièvre, J., López Barragán, M. J., Laurent, V., Su, X.-Z., Berry, A., & Benoit-Vical, F. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01636-09 · Cited by 317 · cited 1×
“After 5 years of artemisinin pressure, the resistant strain F32-ART5 was able to stop multiplying by entering into a quiescent state following treatment with artemisinin [85] as well as with other antimalarial drugs alone such as quinolines (amodiaquine, mefloquine, chloroquine, quinine) or pyrimethamine.”
BackgroundSelf-citationDeclining Artesunate-Mefloquine Efficacy against Falciparum Malaria on the Cambodia–Thailand Border
Wongsrichanalai, C., & Meshnick, S. R. (2008) · Emerging Infectious Diseases · doi:10.3201/eid1405.071601 · Cited by 309 · cited 1×
“In 2006, the declining efficacy of ASMQ was suspected for the first time on the Cambodia-Thailand border [86].”
BackgroundReduced Artemisinin Susceptibility of Plasmodium falciparum Ring Stages in Western Cambodia
Witkowski, B., Khim, N., Chim, P., Kim, S., Ke, S., Kloeung, N., Chy, S., Duong, S., Leang, R., Ringwald, P., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01868-12 · Cited by 308 · cited 1×
“falciparum parasites at the ring stage and is followed by culture in drug-free conditions until the microscopic read-out at 72h [84].”
BackgroundSelf-citationLeang, R., Taylor, W. R. J., Bouth, D. M., Song, L., Tarning, J., Char, M. C., Kim, S., Witkowski, B., Duru, V., Domergue, A., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00835-15 · Cited by 302 · cited 9×
“An increase in concomitant artemisinin and partner drug resistances has been observed in recent years and, as a consequence, treatment failures after ACTs are becoming more widespread in Southeast Asia [24,39,50].”
InfluentialTakala-Harrison, S., Clark, T. G., Jacob, C. G., Cummings, M. P., Miotto, O., Dondorp, A. M., Fukuda, M. M., Nosten, F., Noedl, H., Imwong, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211205110 · Cited by 266 · cited 1×
“The high survival rate of parasites in RSA correlates with both pfk13 polymorphisms and clinical outcomes [6,74,80].”
BackgroundEmergence of Indigenous Artemisinin-Resistant Plasmodium falciparum in Africa
Lu, F., Culleton, R., Zhang, M., Ramaprasad, A., von Seidlein, L., Zhou, H., Zhu, G., Tang, J., Liu, Y., Wang, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1612765 · Cited by 266 · cited 3×
“been reported in Africa in a man who returned to China after having worked for 20months in Guinea [41].”
BackgroundSpread and evolution of Plasmodium falciparum drug resistance
Mita, T., Tanabe, K., & Kita, K. (2009) · Parasitology International · doi:10.1016/j.parint.2009.04.004 · Cited by 249 · cited 2×
“falciparum resistance, with the potential for it to spread to other malaria-endemic continents [46].”
BackgroundPhyo, A. P., Ashley, E. A., Anderson, T. J. C., Bozdech, Z., Carrara, V. I., Sriprawat, K., Nair, S., White, M. M., Dziekan, J., Ling, C., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw388 · Cited by 244 · cited 3×
“In addition, a prospective study conducted between 2003 and 2013 showed that the increasing prevalence of pfk13 mutations was the decisive factor for the rapid decline in the efficacyofASMQon theThailand-Myanmarborder [60].”
BackgroundMethodSpring, M. D., Lin, J. T., Manning, J. E., Vanachayangkul, P., Somethy, S., Bun, R., Se, Y., Chann, S., Ittiverakul, M., Sia-ngam, P., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)70049-6 · Cited by 244 · cited 1×
“Recent data suggest that piperaquine resistance has developed in a background of artemisinin resistance [3,29,60,68,71].”
BackgroundDihydroartemisinin–Piperaquine Failure in Cambodia
Saunders, D. L., Vanachayangkul, P., & Lon, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1403007 · Cited by 225 · cited 1×
“Recent data suggest that piperaquine resistance has developed in a background of artemisinin resistance [3,29,60,68,71].”
BackgroundWhite, N. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-278 · Cited by 199 · cited 1×
“parasite to be pitted out of the host red blood cells, hence removing them from circulation [12,51,78] and preventing these parasite stages from maturing and sequestering in the vessels.”
BackgroundDuru, V., Khim, N., Leang, R., Kim, S., Domergue, A., Kloeung, N., Ke, S., Chy, S., Eam, R., Khean, C., et al. (2015) · BMC Medicine · doi:10.1186/s12916-015-0539-5 · Cited by 197
The antimalarial drug artemisinin alkylates heme in infected mice
Robert, A., Benoit-Vical, F., Claparols, C., & Meunier, B. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500972102 · Cited by 190
Self-citationLeang, R., Barrette, A., Bouth, D. M., Menard, D., Abdur, R., Duong, S., & Ringwald, P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00686-12 · Cited by 185
Phyo, A. P., Jittamala, P., Nosten, F. H., Pukrittayakamee, S., Imwong, M., White, N. J., Duparc, S., Macintyre, F., Baker, M., & Möhrle, J. J. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00320-5 · Cited by 185 · cited 1×
“vivax) [61], it was recently reported that this is not the case”
BackgroundCombating multidrug‐resistant Plasmodium falciparum malaria
Thu, A. M., Phyo, A. P., Landier, J., Parker, D. M., & Nosten, F. H. (2017) · The FEBS Journal · doi:10.1111/febs.14127 · Cited by 174 · cited 3×
“falciparum in the greater Mekong subregion, where standard courses of ACTs are failing [77].”
BackgroundArtemisinin resistance – modelling the potential human and economic costs
Lubell, Y., Dondorp, A. M., Guerin, P. J., Drake, T., Meek, S. R., Ashley, E. A., Day, N., White, N. J., & White, L. J. (2014) · Malaria Journal · doi:10.1186/1475-2875-13-452 · Cited by 173 · cited 1×
“emergence of artemisinin and ACTs resistance will also lead to a loss of productivity resulting from excess morbidity and mortality [42].”
BackgroundThanh, N. V., Thuy-Nhien, N., Tuyen, N. T. K., Tong, N. T., Nha-Ca, N. T., Dong, L. T., Quang, H. H., Farrar, J., Thwaites, G., White, N. J., et al. (2017) · Malaria Journal · doi:10.1186/s12936-017-1680-8 · Cited by 164 · cited 1×
“Clinical failures after dihydroartemisinin-piperaquine (DHA/PPQ) treatment have also been reported, first in Cambodia in 2013 [37] and later in Vietnam in 2017 [59,76], five and twelve years, respectively, after DHA/”
BackgroundEstimated Under-Five Deaths Associated with Poor-Quality Antimalarials in Sub-Saharan Africa
Renschler, J. P., Walters, K. M., Newton, P. N., & Laxminarayan, R. (2015) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.14-0725 · Cited by 163 · cited 1×
“The consumption of poor-quality antimalarials in SubSaharan Africa has also affected children under five years of age, with an estimated 122,350 avoidable deaths in 2013 [66].”
BackgroundLaufer, M. K., Takala‐Harrison, S., Dzinjalamala, F. K., Stine, O. C., Taylor, T. E., & Plowe, C. V. (2010) · The Journal of Infectious Diseases · doi:10.1086/655659 · Cited by 154
Anderson, T., Nair, S., Nkhoma, S. C., Williams, J. T., Imwong, M., Yi, P., Socheat, D., Das, D., Chotivanich, K., Day, N., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/651562 · Cited by 145 · cited 1×
“Resistance to artemisinins is heritable and therefore has a clear genetic basis [5,62].”
BackgroundCerqueira, G. C., Cheeseman, I. H., Schaffner, S. F., Nair, S., McDew‐White, M., Phyo, A. P., Ashley, E. A., Melnikov, A., Rogov, P., Birren, B. W., et al. (2017) · Genome biology · doi:10.1186/s13059-017-1204-4 · Cited by 136 · cited 1×
“causing resistance to artemisinins is promoted by specific genetic factors in a parasite population [14,45].”
BackgroundStraimer, J., Gnädig, N. F., Stokes, B. H., Ehrenberger, M. A., Crane, A., & Fidock, D. A. (2017) · mBio · doi:10.1128/mbio.00172-17 · Cited by 133 · cited 1×
“Moreover, it has been shown that ozonide OZ277 demonstrates significantly limited in vitro activity against artemisinin-resistant parasites, while OZ439 seems effective against most pfk13-mutated, artemisinin-resistant parasite lines, except for those harbouring the mutation I543T [72].”
BackgroundCooper, R. A., Hartwig, C. L., & Ferdig, M. T. (2005) · Acta Tropica · doi:10.1016/j.actatropica.2005.04.004 · Cited by 125 · cited 1×
“However, this recovered sensitivity is not systematic, as shown in Venezuela, where parasites remained resistant to chloroquine more than 15 years after the cessation of the use of chloroquine [16].”
BackgroundPlasmodium falciparum: multifaceted resistance to artemisinins
Paloque, L., Ramadani, A. P., Mercereau‐Puijalon, O., Augereau, J., & Benoit‐Vical, F. (2016) · Malaria Journal · doi:10.1186/s12936-016-1206-9 · Cited by 121 · cited 1×
“As artemisinin resistance is due to the quiescent state of parasites in the presence of artemisinins [55], the standard in”
BackgroundSelf-citationHow to Contain Artemisinin- and Multidrug-Resistant Falciparum Malaria
Dondorp, A. M., Smithuis, F., Woodrow, C. J., & von Seidlein, L. (2017) · Trends in Parasitology · doi:10.1016/j.pt.2017.01.004 · Cited by 107 · cited 1×
“In TACTs, the third partner drug should have an intermediate half-life so that it can provide an associative protective effect over both the fast-acting artemisinin drug and the long-acting partner drug [20,23,77].”
BackgroundUnderstanding artemisinin-resistant malaria: what a difference a year makes
Fairhurst, R. M. (2015) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000199 · Cited by 107 · cited 1×
“However, not all reported nonsynonymous propeller-domain K13 mutants indicate the emergence of artemisinin resistance [26].”
BackgroundBhattacharjee, S., Coppens, I., Mbengue, A., Suresh, N., Ghorbal, M., Slouka, Z., Safeukui, I., Tang, H., Speicher, D. W., Stahelin, R. V., et al. (2018) · Blood · doi:10.1182/blood-2017-11-814665 · Cited by 103 · cited 1×
“K13 is localised in the reticulum endoplasmic of the parasite [9].”
BackgroundAtaíde, R., Ashley, E. A., Powell, R., Chan, J.-A., Malloy, M. J., O’Flaherty, K., Takashima, E., Langer, C., Tsuboi, T., Dondorp, A. M., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615875114 · Cited by 98
Chen, N., LaCrue, A. N., Teuscher, F., Waters, N. C., Gatton, M. L., Kyle, D. E., & Cheng, Q. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02647-14 · Cited by 82 · cited 1×
“explained by its mode of action, which is based on the inhibition of mitochondrial electron transfer, which is actively maintained in quiescent parasites [15,57].”
BackgroundModeling the molecular basis of atovaquone resistance in parasites and pathogenic fungi
Kessl, J. J., Meshnick, S. R., & Trumpower, B. L. (2007) · Trends in Parasitology · doi:10.1016/j.pt.2007.08.004 · Cited by 79 · cited 1×
“Unfortunately, resistance to atovaquone is easily and quickly selected in the field, independent of artemisinin use [31].”
BackgroundThe return of chloroquine-susceptible Plasmodium falciparum malaria in Zambia
Mwanza, S., Joshi, S. N., Nambozi, M., Chileshe, J., Malunga, P., Kabuya, J.-B. B., Hachizovu, S., Manyando, C., Mulenga, M., & Laufer, M. K. (2016) · Malaria Journal · doi:10.1186/s12936-016-1637-3 · Cited by 77
Peatey, C. L., Chavchich, M., Chen, N., Gresty, K. J., Gray, K.-A., Gatton, M. L., Waters, N. C., & Cheng, Q. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv048 · Cited by 76 · cited 1×
“explained by its mode of action, which is based on the inhibition of mitochondrial electron transfer, which is actively maintained in quiescent parasites [15,57].”
BackgroundWWARN Artemisinin based Combination Therapy (ACT) Africa Baseline Study Group (2015) · BMC Medicine · doi:10.1186/s12916-015-0445-x · Cited by 75
Yang, T., Xie, S. C., Cao, P., Giannangelo, C., McCaw, J. M., Creek, D. J., Charman, S. A., Klonis, N., & Tilley, L. M. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00574-16 · Cited by 72 · cited 1×
“In fact, resistant parasites can exhibit reduced in vitro sensitivity to the ozonide antimalarials, depending on the exposure time [89].”
BackgroundLaurent, B. S., Miller, B., Burton, T. A., Amaratunga, C., Men, S., Sovannaroth, S., Fay, M. P., Miotto, O., Gwadz, R. W., Anderson, J. M., et al. (2015) · Nature Communications · doi:10.1038/ncomms9614 · Cited by 72 · cited 1×
“main African malaria vector, Anopheles gambiae [36].”
Ndour, P. A., Lopera-Mesa, T. M., Diakité, S. A. S., Chiang, S., Mouri, O., Roussel, C., Jauréguiberry, S., Biligui, S., Kendjo, É., Claessens, A., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu427 · Cited by 68 · cited 1×
“parasite to be pitted out of the host red blood cells, hence removing them from circulation [12,51,78] and preventing these parasite stages from maturing and sequestering in the vessels.”
BackgroundFake anti-malarials: start with the facts
Kaur, H., Clarke, S. E., Lalani, M., Phanouvong, S., Guerin, P. J., McLoughlin, A., Wilson, B. K., Deats, M., Plançon, A., Hopkins, H., et al. (2016) · Malaria Journal · doi:10.1186/s12936-016-1096-x · Cited by 62 · cited 1×
“This situation is expected to worsen in other endemic malaria countries with the implementation of ACTs, which are more expensive [30].”
BackgroundNa‐Bangchang, K., Muhamad, P., Ruaengweerayut, R., Chai่jaroenkul, W., & Karbwang, J. (2013) · Malaria Journal · doi:10.1186/1475-2875-12-263 · Cited by 61 · cited 10×
“An increase in concomitant artemisinin and partner drug resistances has been observed in recent years and, as a consequence, treatment failures after ACTs are becoming more widespread in Southeast Asia [24,39,50].”
BackgroundInfluentialInduction of Multidrug Tolerance inPlasmodium falciparumby Extended Artemisinin Pressure
Ménard, S., Haddou, T. B., Ramadani, A. P., Ariey, F., Iriart, X., Beghain, J., Bouchier, C., Witkowski, B., Berry, A., Mercereau‐Puijalon, O., et al. (2015) · Emerging infectious diseases · doi:10.3201/eid2110.150682 · Cited by 61 · cited 2×
“Surprisingly, this pluri-resistance was not associated with any of the known genes involved in resistance to these drugs, except pfk13 [44].”
BackgroundSelf-citationMungthin, M., Khositnithikul, R., Sitthichot, N., Suwandittakul, N., Wattanaveeradej, V., Ward, S. A., & Na‐Bangchang, K. (2010) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2010.10-0339 · Cited by 61 · cited 1×
“failures were reported on the Thailand-Myanmar border in correlationwith delayed parasite clearance time [50] and the amplification of pfmdr1 gene copy numbers [48,58].”
BackgroundAssessing the potential impact of artemisinin and partner drug resistance in sub-Saharan Africa
Slater, H. C., Griffin, J. T., Ghani, A. C., & Okell, L. C. (2016) · Malaria Journal · doi:10.1186/s12936-015-1075-7 · Cited by 60 · cited 1×
“Across Africa, it is estimated that if ACT resistance were similar to the highest levels of artemisinin and partner drug resistance currently observed in Cambodia, there would be 78million additional clinical malaria cases between 2016 and 2020 [69].”
BackgroundLeang, R., Canavati, S. E., Khim, N., Vestergaard, L. S., Borghini-Fuhrer, I., Kim, S., Denis, M. B., Heng, P., Tol, B., Huy, R., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00039-16 · Cited by 56 · cited 1×
“unfortunately, its current efficacy on day 42 was below 90% inWestern Cambodia, an artemisinin-resistance area [38].”
BackgroundWWARN Parasite Clearance Study Group (2015) · Malaria Journal · doi:10.1186/s12936-015-0874-1 · Cited by 55 · cited 1×
“, fever with a possible relation with schizont rupture) and artemisinin dose [88].”
BackgroundEvidence of a Mild Mutator Phenotype in Cambodian Plasmodium falciparum Malaria Parasites
Lee, A. H., & Fidock, D. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154166 · Cited by 54 · cited 2×
“In contrast, evidence of a "mildmutator" phenotype has been shown in two artemisinin-resistant Cambodian isolates [40].”
BackgroundACTwatch Group, Newton, P. N., Hanson, K., & Goodman, C. A. (2017) · Malaria Journal · doi:10.1186/s12936-017-1818-8 · Cited by 42 · cited 1×
“Zambia), non-quality-assured ACTs accounted for 32% to 89% of the total ACTs used, and, surprisingly, nonquality-assured ACTs were more expensive than the quality-assured drugs [52].”
BackgroundEffects of Antimalarial Molecules on the Gametocyte Stage of Plasmodium falciparum: The Debate
Dechy‐Cabaret, O., & Benoit‐Vical, F. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3005898 · Cited by 42 · cited 1×
“the Anopheles mosquito [2], both with direct antigametocyte activity and indirect action via the reduction of the asexual parasite population, which is the source of new gametocytes [18].”
BackgroundSelf-citationKovacs, S., van Eijk, A. M., Sevene, E., Dellicour, S., Weiss, N. S., Emerson, S. S., Steketee, R. W., ter Kuile, F. O., & Stergachis, A. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164963 · Cited by 33 · cited 1×
“has been shown to be safe and does not have greater risks than other antimalarial drugs during these periods [32].”
BackgroundClinical and non-clinical safety of artemisinin derivatives in pregnancy
Gomes, C., Boareto, A. C., & Dalsenter, P. R. (2016) · Reproductive Toxicology · doi:10.1016/j.reprotox.2016.08.003 · Cited by 30 · cited 1×
“The risk-free use of artemisinin derivatives has not been well established in the first trimester of pregnancy [27], which is why the WHO does not recommend the use of these drugs during this period.”
BackgroundPoor response to artesunate treatment in two patients with severe malaria on the Thai–Myanmar border
Phyo, A. P., Win, K., Thu, A. M., Swe, L. L., Htike, H., Beau, C., Sriprawat, K., Winterberg, M., Proux, S., Imwong, M., et al. (2018) · Malaria Journal · doi:10.1186/s12936-018-2182-z · Cited by 26 · cited 1×
“poor responses, and one patient died [63].”
Brown, T. S., Jacob, C. G., da Silva, J. C. F., Takala‐Harrison, S., DJIMDÉ, A. A., Dondorp, A. M., Fukuda, M. M., Noedl, H., Nyunt, M. M., Kyaw, M. P., et al. (2014) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2014.12.010 · Cited by 18 · cited 1×
“However, no correlation between drug resistance emergence and increased mutation rates of the parasite’s genome was found in Southeast Asia, invalidating the hypothesis of a "hypermutator" parasite [11].”
BackgroundAtaíde, R., Powell, R., Moore, K. A., McLean, A. R. D., Phyo, A. P., Nair, S., White, M. M., Anderson, T., Beeson, J. G., Simpson, J. A., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix371 · Cited by 18
Ogouyèmi-Hounto, A., Damien, G. B., Dème, A. B., Ndam, N. T., Assohou, C., Tchonlin, D., Mama, A., Hounkpe, V. O., Moutouama, J. D., Remoué, F., et al. (2016) · Parasite · doi:10.1051/parasite/2016028 · Cited by 13 · cited 14×
“The consumption of poor-quality antimalarials in SubSaharan Africa has also affected children under five years of age, with an estimated 122,350 avoidable deaths in 2013 [66].”
BackgroundInfluential
Metadata
- Authors
- Ouji, M., Augereau, J.-M., Paloque, L., & Benoit-Vical, F.
- Venue
- Parasite
- Publisher
- EDP Sciences
- Published
- 2018
- Volume
- 25
- Pages
- 24
- ISSN
- 1252-607X (ISSN-L)
- 1776-1042
- OpenAlex
- W2799282155
- Cited by
- 181
- References
- 78
- FWCI
- 18.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.